Cholestatic viral hepatitis a with refractory pruritus successfully treated with a combination of molecular adsorbent recirculating system and corticosteroids: A case report
Introduction. Hepatitis A virus is a major cause of acute viral hepatitis worldwide, with approximately 1.5 million cases annually. Clinical manifestations of the hepatitis A virus infection range from asymptomatic to acute liver failure. Cholestatic viral hepatitis A is a rare clinical manifestation characterized by a prolonged course, refractory pruritus, imminent acute liver failure and generally good prognosis. The treatment of pruritus in cholestatic viral hepatitis A can be challenging because a response to conventional therapy is limited. Case report. We present the effects of a combination of pulse doses of prednisolone and two cycles of MARS (Molecular Adsorbent Recirculating System) in the treatment of a young female patient with cholestatic viral hepatitis A. This treatment option significantly reduced the duration of the disease and the intensity of pruritus and led to full recovery of the patient and normalization of laboratory parameters of cholestasis. Conclusion. This treatment combination has proven to have significant and lasting effects with no relapse of pruritus. Low doses of corticosteroids administered for a short time reduce the risk of side effects. The importance of vaccination of international travellers should be also pointed out here.
References
1.
Mathiesen LR. The hepatitis A virus infection. Liver. 1981;1(2):81–109.
2.
Jeong SH, Lee HS. Hepatitis A: Clinical Manifestations and Management. Intervirology. 2010;53(1):15–9.
3.
Daghman D, Rez MS, Soltany A, Alsaleh A. Two case reports of corticosteroid administration-prolonged and pulsed therapy-in treatment of pruritus in cholestatic hepatitis A patients. Oxford Medical Case Reports. 2019;2019(8).
4.
Sponholz C, Matthes K, Rupp D, Backaus W, Klammt S, Karailieva D, et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure – a prospective, randomised crossover study. Critical Care. 20(1).
5.
Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28(41):6653–7.
6.
Miller, Miller, Shao, Weaver, Shimokura, Paul, et al. Seroprevalence of viral hepatitis in Tanzanian adults. Tropical Medicine & International Health. 1998;3(9):757–63.
7.
Vuković B, Rončević N, Borota R. Hepatitis A antibodies in the population of SAP Vojvodina. Military medical examination. 1980;37:85–8.
8.
Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. Journal of Gastroenterology and Hepatology. 1999;14(10):946–59.
9.
Coppola N, Genovese D, Pisaturo M, Taffon S, Argentini C, Pasquale G, et al. Acute Hepatitis with Severe Cholestasis and Prolonged Clinical Course Due to Hepatitis A Virus Ia and Ib Coinfection. Clinical Infectious Diseases. 2007;44(9):e73–7.
10.
Sciot R, Van Damme B, Desmet VJ. Cholestatic features in hepatitis A. Journal of Hepatology. 1986;3(2):172–81.
11.
Piscitani L, Di Vito R, Tunno M, Bonomini M. Successful use of single‐pass albumin dialysis in the correction of severe hyperbilirubinemia in a case of acute hepatitis E. Therapeutic Apheresis and Dialysis. 2023;27(2):278–83.
12.
Lisboa LF, Asthana S, Kremer AE, Swain M, Bagshaw SM, Gibney N, et al. Blood Cytokine, Chemokine and Gene Expression in Cholestasis Patients with Intractable Pruritus Treated with a Molecular Adsorbent Recirculating System: A Case Series. Canadian Journal of Gastroenterology. 2012;26(11):799–805.
13.
Pullukçu H. Use of steroids for prolonged cholestasis secondary to acute hepatitis A infection. Journal of Microbiology and Infectious Diseases. 2014;4(4):162–4.
14.
Autor. Albumin dialysis: basic principles and clinical significance (in Serbian): Autor. Liver diseases and kidney damage in clinical practice. 2018.
15.
Gavrilovic J, Velickovic JD, Mijailovic Z, Lazarevic T, Gavrilovic A, Tomovic M. Applying the Molecular Adsorbent Recirculating System (MARS) in the Treatment of Acute Liver Failure (ALF) Case Report. Serbian Journal of Experimental and Clinical Research. 2018;19(2):189–94.
16.
Acevedo Ribó M, Moreno Planas JM, Sanz Moreno C, Rubio González EE, Rubio González E, Boullosa Graña E, et al. Therapy of Intractable Pruritus With MARS. Transplantation Proceedings. 2005;37(3):1480–1.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
